(CercleFinance.com) — Onxeo lifted the veil on Thursday on a second drug candidate for the treatment of solid tumors, from its proprietary decoy oligonucleotide platform.
The biotech company explains that OX425 leads to hyperactivation of human PARP-1 polymerases, leading to exhaustion of the DNA damage response and inducing cancer cell death.
In preclinical proof-of-concept studies, OX425 demonstrated high antitumor activity while sparing healthy cells, the company said in a statement.
This compound has also shown the ability to produce multiple immunostimulatory effects, making it, according to Onxeo, a “promising” option for a potential combination with immunotherapy.
The biotech now says it is finalizing its preclinical development with the goal of filing an Investigational New Drug File (IND) with the US FDA in the middle of next year.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
